Discovery and fine-mapping of adiposity loci using high density imputation of genomewide association studies in individuals of African ancestry: African Ancestry Anthropometry Genetics Consortium

Mary F. Feitosa  
*Washington University School of Medicine in St. Louis*

Mary K. Wojczynski  
*Washington University School of Medicine in St. Louis*

D. C. Rao  
*Washington University School of Medicine in St. Louis*

Ingrid B. Borecki  
*Washington University School of Medicine in St. Louis*

et al.

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
https://digitalcommons.wustl.edu/open_access_pubs/5970

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Discovery and fine-mapping of adiposity loci using high density imputation of genome-wide association studies in individuals of African ancestry: African Ancestry Anthropometry Genetics Consortium


1 Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, NC, United States of America, 2 Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC, United States of America, 3 Department of Epidemiology, University of North Carolina, Chapel Hill, NC, United States of America, 4 The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America, 5 Department of Biostatistics, Boston University School of Public Health, Boston, MA, United States of America, 6 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America, 7 Division of Statistical Genetics, Department of Genetics, Washington University School of Medicine, St. Louis MO, United States of America, 8 Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States of America, 9 Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, United States of America, 10 Division of Sleep and Circadian Disorders, Brigham and Women’s Hospital, Boston, MA, United States of America, 11 Harvard Medical School, Boston, MA, United States of America, 12 Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America, 13 Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, United States of America, 14 Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, United States of America, 15 Data Tecnica
GWAS for adiposity in African ancestry

PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006719 April 21, 2017 2 / 25

CA1325792, CA148085, HG004726 and a Department of Defense Breast Cancer Research Program Era of Hope Scholar Award to CAH (W81XWH-08-1-0383) and the Norris Foundation. AABC-CARE: CARE was supported by National Institute for Child Health and Development contract N01-HD-3-3175. AABC-WCHS: WCHS is supported by a U.S. Army Medical Research and Material Command (USAMRMC) grant DAMD-17-01-0-0334, National Institutes of Health grant CA100598, and the Breast Cancer Research Foundation. AABC-SFBCS: SFBCS was supported by National Institutes of Health grant CA77305 and United States Army Medical Research Program grant DAMD17-96-6071. AABC-NC-BCFR: The Breast Cancer Family Registry (BCFR) was supported by the National Cancer Institute, National Institutes of Health under RFA CA-06-503 and through cooperative agreements with members of the Breast Cancer Family Registry and Principal Investigators, including the Cancer Prevention Institute of California (U01 CA69417). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government or the BCFR. AABC-CBCS: CBCS is supported by National Institutes of Health Specialized Program of Research Excellence in Breast Cancer grant C52823 and Center for Environmental Health and Susceptibility, National Institute of Environmental Health Sciences, National Institutes of Health, grant ES10126. AABC-PLCO: Genotyping of the PLCO samples was funded by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, the National Institutes of Health. The authors thank Drs. Christine Berg and Philip Prorok, Division of Cancer Prevention, National Cancer Institute, the screening center investigators and staff of the PLCO Cancer Screening Trial, Mr. Thomas Riley and staff at Information Management Services, Inc., and Ms. Barbara O’Brien and staff at Westat, Inc. for their contributions to the PLCO Cancer Screening Trial. AABC-NBH: NBHS is supported by National Institutes of Health grant CA100374. NBHS sample preparation was conducted at the Biospecimen Core Lab that is supported in part by the Vanderbilt-Ingram Cancer Center (CA68485). AABC-WFBC: WFBC is supported by National Institutes of Health grants CA73629. APCR-CPS-II: CPSII is supported by the American Cancer Society. APCR-KCPCS: KCPCS was supported by National Institutes of Health grants CA056678, CA082664 and CA092579, with additional support International, Glen Echo, MD, United States of America, 16 National Institute on Aging, National Institutes of Health, Baltimore, MD, United States of America, 17 Department of Public Health Sciences, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, United States of America, 18 Division of Endocrinology and Center for Basic and Translational Obesity Research, Boston Children’s Hospital, Boston, MA, United States of America, 19 Broad Institute of MIT and Harvard, Cambridge, MA, United States of America, 20 Center for Applied Genomics, The Children’s Hospital of Philadelphia, Philadelphia, PA, United States of America, 21 Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, United States of America, 22 Department of Public Health Sciences and Center for Public Health Genomics, University of Virginia School of Medicine, Charlottesville, VA, United States of America, 23 Division of Human Genetics, The Children’s Hospital of Philadelphia, Philadelphia, PA, United States of America, 24 Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States of America, 25 Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, MI, United States of America, 26 Department of Epidemiology, University of Michigan, Ann Arbor, MI, United States of America, 27 Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, TN, United States of America, 28 Division of Preventive Medicine, Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA, United States of America, 29 Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, United States of America, 30 Department of Population Science, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States of America, 31 Cardiovascular Health Research Unit, Departments of Medicine and Biostatistics, University of Washington, Seattle, WA, United States of America, 32 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, United States of America, 33 Beckman Research Institute of the City of Hope, Duarte, CA, United States of America, 34 International Epidemiology Institute, Rockville, MD, United States of America, 35 Department of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States of America, 36 Center for Human Genetics, University of Texas Health Science Center at Houston, Houston, TX, United States of America, 37 Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, United States of America, 38 SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America, 39 Program in Bioinformatics and Integrative Genomics, Harvard Medical School, Boston, MA, United States of America, 40 Sylvester Comprehensive Cancer Center, University of Miami Leonard Miller School of Medicine, Miami, FL, United States of America, 41 Department of Public Health Sciences, University of Miami Leonard Miller School of Medicine, Miami, FL, United States of America, 42 Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, TX, United States of America, 43 Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, United States of America, 44 Cancer Prevention Institute of California, Fremont, CA, United States of America, 45 Department of Health Research and Policy (Epidemiology) and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, United States of America, 46 Division of Urology, Department of Surgery, The University of Arizona, Tucson, AZ, United States of America, 47 Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, United States of America, 48 Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, United States of America, 49 Cardiovascular Health Research Unit, Department of Biostatistics, University of Washington, Seattle, WA, United States of America, 50 Center for Public Health Genomics, University of Virginia School of Medicine, Charlottesville, VA, United States of America, 51 Department of Preventive Medicine, Stony Brook University, Stony Brook, NY, United States of America, 52 Department of Medicine, University of Ibadan, Ibadan, Nigeria, 53 Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, Chapel Hill, NC, United States of America, 54 Department of Pathology and Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States of America, 55 Department of Public Health Sciences, Henry Ford Health System, Detroit, MI, United States of America, 56 Department of Family and Community Medicine, Meharry Medical College, Nashville, TN, United States of America, 57 The New York Academy of Medicine, New York, NY, United States of America, 58 Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America, 59 Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, United States of America, 60 Epidemiology Research Program, American Cancer Society, Atlanta, GA, United States of America, 61 Department of Epidemiology, Bloomberg School of Public Health, Baltimore, MD, United States of America, 62 Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, United States of America, 63 Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, United States of America, 64 Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, United States of America, 65 Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States of America, 66 Laboratory of Human Carcinogenesis, National Cancer Institute, Bethesda, MD, United States of America, 67 Department of Medicine, University of Vermont College of Medicine, Burlington, VT, United States of America, 68 Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI, United States of America, 69 Department of Pediatrics, Perelman School of
Abstract

Genome-wide association studies (GWAS) have identified >300 loci associated with measures of adiposity including body mass index (BMI) and waist-to-hip ratio (adjusted for BMI, WHR<sub>adjBMI</sub>), but few have been identified through screening of the African ancestry genomes. We performed large scale meta-analyses and replications in up to 52,895 individuals for BMI and up to 23,095 individuals for WHR<sub>adjBMI</sub> from the African Ancestry Anthro-pometry Genetics Consortium (AAAGC) using 1000 Genomes phase 1 imputed GWAS to improve coverage of both common and low frequency variants in the low linkage disequilibrium African ancestry genomes. In the sex-combined analyses, we identified one novel locus (TCF7L2/HABP2) for WHR<sub>adjBMI</sub> and eight previously established loci at P < 5 × 10<sup>−8</sup> for BMI, and one for WHR<sub>adjBMI</sub> in African ancestry individuals. An additional novel locus (SPRYD7/DLEU2) was identified for WHR<sub>adjBMI</sub> when combined with European GWAS. In the sex-stratified analyses, we identified three novel loci for BMI (INTS10/LPL and MLC1 in men, IRX4/IRX2 in women) and four for WHR<sub>adjBMI</sub> (SSX2IP, CASC8, PDE3B and ZDHHC1/HSD11B2 in women) in individuals of African ancestry or both African and European ancestry. For four of the novel variants, the minor allele frequency was low (<5%). In the trans-ethnic fine mapping of 47 BMI loci and 27 WHR<sub>adjBMI</sub> loci that were locus-wide significant (P < 0.05 adjusted for effective number of variants per locus) from the African ancestry sex-combined and sex-stratified analyses, 26 BMI loci and 17 WHR<sub>adjBMI</sub> loci contained ≤ 20 variants in the credible sets that jointly account for 99% posterior probability of driving the associations. The lead variants in 13 of these loci had a high probability of being causal. As compared to our previous HapMap imputed GWAS for BMI and WHR<sub>adjBMI</sub>...
Introduction

Obesity is a worldwide public health epidemic, with current US estimates of 37.9% obese and 7.7% morbidly obese adults [1]. Disparities in obesity rates, as well as rates of comorbidities and mortality, are evident across sex and racial/ethnic groups. Estimates from NHANES for 2013–2014 [1] show that obesity is more prevalent among African Americans (48.5%) than among non-Hispanic Whites (37.1%). In addition, obesity rates are higher among African American women (57.2%) than among African American men (38.2%). For comparison, the obesity rates in non-Hispanic Whites were 38.7% and 35.4%, respectively, for women and men.

Genome-wide association studies (GWAS) in diverse populations have identified > 300 loci associated with measures of adiposity including body mass index (BMI) and waist-to-hip ratio (adjusted for BMI, WHRadjBMI) in populations of European ancestry [2–9], African ancestry [10–12], and East Asian ancestry [13–15]. The majority of associated variants are common (MAF > 5%) with small effect size, and jointly explain only a fraction of the phenotypic variances [7–8]. It has long been hypothesized that low frequency (MAF = 0.5–5%) and rare (MAF < 0.5%) variants may also contribute to variability in complex traits. However, these variants are not well captured in previous GWAS imputed to the HapMap reference panel [16–17]. The availability of higher density reference panels such as the 1000 Genomes Project (38M variants in 1092 individuals from phase 1) [18] has demonstrated improved imputation quality in European populations particularly for low frequency variants (aggregate R² ~0.6 for MAF = 0.5%). However, its impact is less clear for non-European populations [19]. We took this opportunity to use higher density imputation to reevaluate our previous GWAS for associations with anthropometric traits in individuals of African ancestry (AA) including African Americans and Africans.
The African Ancestry Anthropometry Genetics Consortium (AAAGC) previously identified seven genome-wide significant loci for BMI in up to 71,412 AA individuals, and an additional locus when combined with European ancestry (EA) data from the Genetic Investigation of Anthropometric Traits (GIANT) consortium using GWAS imputed to the HapMap Phase 2 reference panel [11]. No genome-wide significant loci were identified for WHR\(_{\text{adjBMI}}\) in a GWAS of up to 27,350 AA individuals [12]. The low yield of discovery in AA studies is likely due to their relatively smaller sample sizes in comparison to EA studies [7–8], as well as their lower degree of linkage disequilibrium (LD) and thus poorer imputation quality. Here, we extended our previous work in the AAAGC to perform meta-analyses and replication of GWAS imputed to the 1000 Genomes reference panel in up to 52,895 AA individuals for BMI and up to 23,095 AA individuals for WHR\(_{\text{adjBMI}}\). We aimed to 1) discover novel variants, 2) fine map established loci, and 3) evaluate the coverage and contribution of low frequency variants in genetic associations in AA populations.

**Results**

**Study overview**

We conducted sex-combined and sex-stratified meta-analyses of GWAS summary statistics across 17 studies for BMI (N = 42,752) and 10 studies for WHR\(_{\text{adjBMI}}\) (N = 20,384) in AA individuals in stage 1 discovery (S1 and S2 Tables, S1 Fig). Missing genotypes in individual studies were imputed to the 1000 Genomes Project cosmopolitan reference panel (Phase 1 Integrated Release Version 3, March 2012) [18] using MaCH/minimac [20] or SHAPEIT2/IMPUTE2 [21–22] (S3 Table). Genomic control corrections were applied to each study and after meta-analysis (\(\lambda = 1.07\) for BMI, 1.01 for WHR\(_{\text{adjBMI}}\)) (S3 Table, S2–S5 Figs). Association results for \(\sim 18M\) variants for BMI and \(\sim 21M\) variants for WHR\(_{\text{adjBMI}}\) were subsequently interrogated further.

From stage 1 meta-analyses, variants associated with BMI (3,241 in all, 1,498 in men, 2,922 in women) and WHR\(_{\text{adjBMI}}\) (2,496 in all, 1,408 in men, 2,827 in women) at \(P < 1 \times 10^{-4}\) were carried forward for replication in AA and EA. Stage 2 included 10,143 AA (2,458 men and 7,685 women) for BMI and 2,711 AA (981 men and 1,730 women) for WHR\(_{\text{adjBMI}}\) analyses. Stage 3 included 322,154 EA (152,893 men and 171,977 women) for BMI and 210,086 EA (104,079 men and 116,742 women) for WHR\(_{\text{adjBMI}}\) analyses by imputing HapMap summary statistics results [7–8] to 1000 Genomes [23] (S1 Fig). Meta-analyses were performed to combine either sex-combined or sex-specific results from AA (stages 1+2, N \(\leq 57,985\) for BMI, \(\leq 23,095\) for WHR\(_{\text{adjBMI}}\) in sex-combined analyses) and both AA and EA (stages 1+2+3, N \(\leq 380,049\) for BMI, \(\leq 233,181\) for WHR\(_{\text{adjBMI}}\) in sex-combined analyses, S6–S9 Figs). Variants that reached genome-wide statistical significance (\(P < 5 \times 10^{-8}\)) were assessed for generalization of associations with BMI to children in two additional AA cohorts (N = 7,222).

**Genome-wide significant loci in meta-analyses**

**Sex-combined analyses.** In the sex-combined meta-analysis of BMI in AA, seven previously established European or African ancestry-derived loci in/near SEC16B, TMEM18, GNPDA2, GALNT10, KLHL32, FTO and MC4R reached genome-wide significance (\(P < 5 \times 10^{-8}\)) (Table 1, S6 and S10A Figs). The rs7708584 variant at GALNT10 had the lowest P-value (\(P = 4.2 \times 10^{-14}\)) and was the same lead variant as reported in our previous AA study (S5 Table) [11]. The association at KLHL32 was specific to the AA population as the lead variant was not statistically significant in EA (\(P > 0.05\)), consistent with our previous finding (S5 Table) [11]. No additional novel BMI loci were identified after meta-analysis of AA and EA.
HHSN268201300047C, HHSN268201300048C, HHSN268201300049C, HHSN268201300050C from the National Heart, Lung, and Blood Institute and the National Institute on Minority Health and Health Disparities. JGW is supported by US4GM115428 from the National Institute of General Medical Sciences. Meywood: NIH: R37-HL045508, R01-HL074166, R01-HL086718, R01-HG003054; analysis also funded through R01-DK075787. MESA: The Multi-Ethnic Study of Atherosclerosis study (MESA) was supported by the Multi-Ethnic Study of Atherosclerosis (MESA) contracts N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169 and by grants UL1-TR-000040 and UL1-RR-025005 from NCRR. Funding for MESA SHARE genotyping was provided by NHLBI Contract N02-HL-6-4276. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSA grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. Nigeria: NIH: R37-HL045508, R01-HL063533, R01-DK075787 and U01-HL054512; analysis also funded through R01-DK075787. ROOT: NIH: R01-CA142996, PS0-Ca125183, R01-CA89085, and U01-CA161002. American Cancer Society: MRSG-13-063-01-TG and CRP-10-119-01-CC. SAPPHIRE: NIH/NHLBI R01HL118267; NIH/NIAID R01AI079139; NIH/NIDDK R01DK064695 and R01DK113003. American Asthma Foundation. SIGNET-REGARDS: The Sea Islands Genetics Network (SIGNET) was supported by R01 DK084350 (MM Sale). The authors thank the other investigators, the staff, and the participants of the REGARDS study for their valuable contributions. A full list of participating REGARDS investigators and institutions can be found at http://www.regardsstudy.org. This study (REGARDS) was supported by a cooperative agreement U01 NS041588 from the National Institute of Neurological Disorders and Stroke (NINDS). WFSM: Genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268200728096C. This work was supported by National Institutes of Health grants R01 DK087914, R01 DK066358, R01 DK053591, R01 HL05266, R01 DK070941 and by the Wake Forest School of Medicine grant M01 RR07122 and Venture Fund 20543. WHI: Funding support for the data. Two previously reported loci in AA, ADCY3 and MIR148A-NFE2L3 [11], did not reach genome-wide significance in the present study. The previously reported lead variant at ADCY3, rs7586879, showed weaker effect and association in AA (effect = 0.047, P = 3.60×10⁻⁸ [11] vs. effect = 0.052, P = 1.05×10⁻⁴, this study). On the other hand, a moderately correlated (r² = 0.52 in AFR) variant, rs10203482, show stronger association at P = 3.35×10⁻⁷ (S5 Table). At MIR148A/NFE2L3, the previously reported lead variant identified by meta-analysis of AA and EA, rs10261878, also showed weaker association in the current study primarily due to weak association in EA (P = 4.10×10⁻⁸ in AA, 4.69×10⁻³ in EA and 2.10×10⁻⁵ in AA+EA) (S5 Table). For WHRadjBMI, an established locus (ADAMT59-AS2) (S10B Fig) and a novel locus (TCF7L2/HAPBP2) (Fig 1A) showed significant associations, the latter lead variant rs16718588 was low frequency (MAF = 0.045, Table 1). Meta-analyses including both AA and EA individuals revealed an additional novel locus at SPRYD7/DLEU2 for WHRadjBMI (Table 1, Fig 1A and S7 Fig). Overall, all the BMI associated lead variants were present in HapMap and were in high LD (r² > 0.5) in 1000 Genomes AFR population with the lead variants in our previous HapMap imputed data, except for TMEM18 rs62105306 (r² = 0.17) which is absent in HapMap. In contrast, all three WHRadjBMI lead variants were absent in HapMap and the lead variants at ADAMTS9-AS2 and TCF7L2-HAPBP2 were in low LD (r² < 0.5) with the lead variants in our previous HapMap imputed data [11–12]. We used conditional and joint association analyses to examine the genome-wide significant locus for secondary signals, but no additional independent signals were found.

**Sex-stratified analyses.** In the sex-stratified meta-analysis in AA, four established BMI loci (SEC16B, GALNT10, FTO and MC4R) and one established WHRadjBMI locus (ADAMT59-AS2) were genome-wide significant among women (S6 Table, S8 and S9 Figs). ADAMT59-AS2 showed a stronger association with WHRadjBMI among women than among men (Phet = 0.02) (S6 Table), consistent with findings among EA [9]. On the other hand, although our observed SEC16B rs543874 effect size differences (0.064 vs. 0.038, Phet = 0.08) for BMI in women compared to men were similar to those previously observed among EA (0.060 vs. 0.034, Phet = 5.23×10⁻⁵) [7], we did not observe statistically significant differences in effect size, likely due to a much smaller sample size and thus lower statistical power in our study. All these five loci were also genome-wide significant in the sex-combined meta-analyses. They were not further examined in subsequent sex-stratified analyses given their smaller sample sizes compared to the sex-combined analyses. In AA, additional novel loci were observed for association with BMI; these variants were in IRX4/IRX2 among women, variants in INTS10/LPL and MLC1 among men (Fig 2), and for WHRadjBMI, variants in SXX2IP and PDE3B among women (Fig 1B, Table 2). In meta-analyses including both AA and EA, two additional novel loci at CASC8 and ZDHHC1/HSI12B2 were identified for WHRadjBMI in women (Table 2, Fig 1B). Among all loci, the effect sizes of six variants (IRX4/IRX2, INTS10/LPL, MLC1, ADAMT59-AS2, PDE3B and CASC8) were nominally significant different between men and women in AA (Phet < 0.05) (S6 Table).

**Replication in children.** We evaluated the seven sex-combined and three sex-specific genome-wide significant BMI loci for associations in 7,222 AA children (3,552 boys and 3,670 girls). All lead variants displayed directional consistency, and five of these including SEC16B, TMEM18, GNPD2A, GALNT10 and MC4R showed nominal associations with BMI (P < 0.05, Pbinomial = 4.70×10⁻⁸) (S7 Table), supporting the role of these loci in modulating adiposity in AA children. WHRadjBMI data were not available in the cohorts of children.

**Functional characterization of novel loci.** We used multiple complementary approaches to elucidate the putative causal genes and/or variants associated with the nine novel BMI and WHRadjBMI loci from the sex-combined and sex-stratified analyses, including annotating nearby coding variants, cis-expression quantitative trait loci (cis-eQTL) analyses, and
function of regulatory genomic element analyses. One missense variant in PLEKHG4, rs8044843, was in high LD ($r^2 = 0.75$ in AFR) with rs6499129 associated with WHR$_{adjBMI}$ in women (S8 Table). We did not identify any coding variants in high LD ($r^2 > 0.7$) with other lead variants within the flanking 1Mb-regions. Regulatory element analyses using RegulomeDB [24] and HaplReg [25] revealed that proxies ($r^2 = 0.73–0.84$) to lead variants at three WHR$_{adjBMI}$ loci (SPRYD7/DLEU2, PDE3B, and ZDHHC1/HSD11B2) were associated with transcription factor binding, DNase peak, promoter or enhancer histone marks (S8 Table). In addition, the lead variant rs2472591 at SPRYD7/DLEU2 was in high LD ($r^2 = 0.85$) with rs790943, a cis-eQTL associated with expression of the nearby gene, TRIM13, in blood dendritic cells in tuberculosis patients [26] (S9 Table), suggesting the associations at the SPRYD7/DLEU2 locus may be involved in the regulation of nearby gene expression at TRIM13.

**Cross-trait associations of novel loci.** We searched the NHGRI-EBI GWAS [27] and Genome-Wide Repository of Associations Between SNPs and Phenotypes (GRASP) [28] catalogs to assess if any of the nine novel lead variants were in high LD with variants that were genome-wide significantly ($P < 5 \times 10^{-8}$) or nominally ($P < 0.05$) associated with related anthropometric and cardiometabolic traits or gene expression in prior studies. Although a few lead variants were physically close (<500 kb) to GWAS loci for related traits in the NHGRI-EBI GWAS Catalog (Figs 1 and 2), none of our lead variants were in high LD with the previously associated lead variants. Additionally, there were no nearby associations for novel BMI loci in the GRASP Catalog. Of the novel variants associated with WHR$_{adjBMI}$, rs2472591 at SPRYD7/DLEU2, rs378854 near MYC, and rs6499129 near ZDHHC1/HSD11B2 were in high LD ($r^2 > 0.7$) with previously-reported WHR$_{adjBMI}$ variants, but they did not reach genome-wide significance ($P > 2 \times 10^{-7}$) [3] (S9 Table). Other nearby associations with related cardiometabolic traits include chronic kidney disease (CKD), high density lipoprotein cholesterol (HDL-C), anthropometric traits (BMI, height, and birth weight), blood pressure (systolic blood pressure and hypertension), diabetes-related traits (blood glucose and HOMA-IR), and gene expression of several genes (e.g. ATP6V0D1, ZDHHC1, DUS2L, AGRP, GFD2 and LRRC29).

**Evaluation of established European loci in African ancestry populations**

**Conditional analysis in GWAS loci.** Among the six BMI (SEC16B, TMEM18, GNPDA2, GALNT10, FTO and MC4R) and one WHR$_{adjBMI}$ (ADAMTS9-AS2) genome-wide significant loci in AA that were previously reported in EA [7–8], we tested whether the African derived lead variants were independent of the reported European signals by conditioning on the European lead variants or their surrogates. For three of the BMI loci (SEC16B, GNPDA2 and MC4R), our lead variants are the same as those reported in the previous literature [7]. For all other loci, the lead variants demonstrated substantially lower significance upon conditional analysis, suggesting that the African ancestry results represented the same association signals as previously reported in GWAS performed predominantly in EA populations (S10 Table).

**SNP transferability.** We further examined all sex-combined and sex-stratified BMI and WHR$_{adjBMI}$ loci identified from previous EA studies [7–9] in our AA data. Among 176 EA lead variants from 170 BMI loci, 119 variants displayed directionally consistent associations with BMI in our data, 31 of these were nominally significant at $P < 0.05$ ($P_{binomial} = 2.2 \times 10^{-18}$ among 176 variants). Among 84 EA lead variants from 65 WHR$_{adjBMI}$ loci, 69 variants displayed directionally consistent associations with WHR$_{adjBMI}$, and 23 of these were nominally significant ($P_{binomial} = 5.3 \times 10^{-19}$ among 84 variants) (S11 Table). EA lead variants in 11 BMI and 3 WHR$_{adjBMI}$ loci showed directional consistency and significant associations after correction for multiple comparisons ($P < 1.92 \times 10^{-4}$). Among the 54 nominally transferable lead
Table 1. Novel and previously identified BMI and WHRadjBMI loci at $P < 5 \times 10^{-8}$ in African ancestry discovery and replication samples, and European ancestry replication samples.

| Trait | Lead SNP | Chr | Position (b37/hg19) | Known Locus (if Yes, lead published variant) | Locus | Effect/Other alleles | EAF | Effect (SE) | HEtISq | N | Effect (SE) | HEtISq | N | Effect (SE) | HEtISq | N | Effect (SE) | HEtISq | N | Effect (SE) | HEtISq | N | Effect (SE) | HEtISq | N | Effect (SE) | HEtISq | N | Effect (SE) | HEtISq | N |
|-------|----------|-----|---------------------|-------------------------------------------|-------|---------------------|-----|--------------|-------|-----|--------------|-------|-----|--------------|-------|-----|--------------|-------|-----|--------------|-------|-----|--------------|-------|-----|--------------|-------|-----|--------------|-------|-----|--------------|-------|-----|
| BMI   | rs543874 | 1   | 177,889,480         | Yes rs543874                               | SEC16B| G/A                | 0.248 | 0.055 (0.008) | 5.75E-11 | 0 | 42,681       | 0.057 (0.017) | 6.59E-04 | 28.9 | 10,143       | 0.055 (0.008) | 4.36E-01 | 322,008 | 6.35E-06 |
| BMI   | rs62105306 | 2   | 633,660             | Yes rs13021737                              | TMEM18| T/C                | 0.751 | 0.056 (0.011) | 1.55E-08 | 0 | 41,492       | 0.04 (0.02) | 4.40E-02 | 49.4  | 10,143       | 0.053 (0.009) | 2.17E-09  | 6.10E-21 | 244,176 | 3.04E-28 |
| BMI   | rs10938397 | 4   | 45,182,527          | Yes rs10938397                              | GNPD2A| G/A                | 0.243 | 0.053 (0.008) | 3.76E-10 | 3.6 | 42,752       | 0.111 (0.017) | 5.40E-01 | 54.0  | 10,143       | 0.044 (0.008) | 3.95E-09  | 1.87E-38 | 320,955 | 5.60E-46 |
| BMI   | rs17057164 | 6   | 97,410,536          | Yes rs974417; rs7708584                      | GALT10| A/G                | 0.307 | 0.059 (0.008) | 1.05E-13 | 4.6 | 42,750       | 0.034 (0.016) | 3.93E-02 | 6.2   | 10,143       | 0.054 (0.007) | 4.21E-14  | 3.80E-07 | 234,015 | 4.35E-15 |
| BMI   | rs17817964 | 16  | 53,828,066          | Yes rs1558902                               | KLHL32| T/C                | 0.659 | 0.043 (0.008) | 1.75E-08 | 0   | 42,751       | 0.025 (0.015) | 9.97E-02 | 35.2  | 10,143       | 0.04 (0.007)  | 6.08E-09  | 7.44E-01 | 233,997 | 5.43E-03 |
| BMI   | rs6567160  | 18  | 57,829,135          | Yes rs6567160                               | MC4R  | C/T                | 0.197 | 0.062 (0.009) | 2.74E-11 | 35.3| 42,750       | 0.044 (0.019) | 1.99E-02 | 33.5  | 10,143       | 0.059 (0.008) | 2.23E-12  | 2.83E-04 | 321,958 | 2.09E-04 |
| WHR   | rs6615866  | 3   | 64,703,394          | Yes rs1558902                               | ADAMTS9-AS2 | G/T | 0.457 | 0.07 (0.011) | 3.90E-12 | 20,383 | 0.005 (0.033) | 8.75E-01 | 42.1 | 2,711 | 0.064 (0.011) | 2.46E-11 | 5.17E-19 | 145,257 | 9.13E-27 |
| WHR   | rs116718588 | 10  | 115,189,239         | No TCF7L2/ HABP2                           | 0.114 | 0.055 (0.025) | 5.88E-12 | 20,384 | 0.034 (0.084) | 3.82E-05 | 45.6 | 2,711 | 0.134 (0.024) | 3.22E-08 | NA  | NA          | NA      | NA  | NA          | NA      | NA  |
| WHR   | rs2472591  | 13  | 50,536,360          | No SPRYD7/ DLEU2                          | 0.058 | 0.05 (0.013) | 9.32E-05 | 20,371 | 0.06 (0.049) | 2.21E-01 | 0   | 2,160 | 0.05 (0.012) | 4.35E-05 | 1.69E-05 | 140,431 | 3.53E-08 |

AA: African ancestry; BMI: body mass index; Chr: chromosome; EA: European ancestry; EAF: effect allele frequency; HEtISq: heterogeneity measured by I-square; SE: standard error; WHRadjBMI: waist-to-hip ratio adjusted for BMI

a lead published variants reported in African ancestry

https://doi.org/10.1371/journal.pgen.1006719.t001
Fig 1. Locuszoom plots of six novel waist-to-hip ratio adjusted for BMI (WHRadjBMI) loci: (A) TCF7L2/HABP2 and SPRYD7/DLEU2 in men and women combined; and (B) SSX2IP, PDE3B, CASC8, and ZDHHC1/HSD11B2 in women only. All plots use AFR LD from the 1000 Genomes phase 1 reference panel. In each plot, the most significant variant within a 1Mb regional locus is highlighted. P-values for all variants including the most significant variant are based on the African ancestry discovery phase only (AA-Discovery). In addition, for the most significant variant, P-values are annotated and illustrated from the African ancestry discovery and replication phases (AA-Discovery+Replication). SNP rs2472591 was available in the Europeans from the GIANT consortium effort and combined with the African ancestry discovery and replication phases (AA+EA).

https://doi.org/10.1371/journal.pgen.1006719.g001
variants for BMI and WHR_{adjBMI}. 45% and 43% of the effect sizes, respectively, were larger in the EA than the AA populations. In addition, 65% of the frequencies of the trait-raising alleles were higher in the EA populations for both traits. The correlations of both effect sizes and allele frequency of the transferable variants were high (0.74 and 0.79, respectively) for BMI but weak (0.19 and 0.37, respectively) for WHR_{adjBMI} (S11 Fig). The significant but low proportion of lead variants that were transferable from EA to AA (18% for BMI and 27% for WHR_{adjBMI}) suggests either that many loci are not implicated in AA or population differences in LD mask the detection of associated variants in AA. On the other hand, those variants that were transferable explain similar levels of variances for BMI in both populations, but not for WHR_{adjBMI}.

**Locus transferability.** We further investigated locus transferability in EA loci derived from sex-combined and sex-stratified analyses by considering varying LD between EA and AA populations. S12 Table reports the most significant lead regional variants in our AA sex-combined and sex-stratified data within 0.1cM region of the previously published EA loci (from 176 BMI and 84 WHR_{adjBMI} lead variants) [7–8]. Forty-five (26%) lead regional variants from
Table 2. Additional novel BMI and WHR\textsubscript{adjBMI} loci at \(P < 5 \times 10^{-8}\) in sex-stratified analyses of African ancestry discovery and replication samples.

<table>
<thead>
<tr>
<th>Trait</th>
<th>Cohort</th>
<th>Lead SNP</th>
<th>Chr</th>
<th>Position (b37/hg19)</th>
<th>Locus</th>
<th>Effect/Other alleles</th>
<th>EAF</th>
<th>Effect (SE)</th>
<th>(P)</th>
<th>HetISq</th>
<th>(N)</th>
<th>Effect (SE)</th>
<th>(P)</th>
<th>HetISq</th>
<th>(N)</th>
<th>Effect (SE)</th>
<th>(P)</th>
<th>EA</th>
<th>AA + EA</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI</td>
<td>Women</td>
<td>rs112778462</td>
<td>5</td>
<td>2,177,693</td>
<td>IRX4/IRX2</td>
<td>G/A</td>
<td>0.023</td>
<td>0.159</td>
<td>0.035</td>
<td>6.06E-06</td>
<td>35.4</td>
<td>25,792</td>
<td>0.219</td>
<td>0.059</td>
<td>2.11E-04</td>
<td>47.6</td>
<td>6,984</td>
<td>0.175</td>
<td>7.21E-09</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td>Men</td>
<td>rs149352150</td>
<td>8</td>
<td>19,736,154</td>
<td>INTS10/</td>
<td>G/A</td>
<td>0.013</td>
<td>0.341</td>
<td>0.058</td>
<td>4.29E-09</td>
<td>0</td>
<td>15,179</td>
<td>-0.034</td>
<td>0.163</td>
<td>8.35E-01</td>
<td>1.0</td>
<td>2,147</td>
<td>0.299</td>
<td>4.68E-08</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>LPA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td>Men</td>
<td>rs56330886</td>
<td>22</td>
<td>50,493,427</td>
<td>MLCP1</td>
<td>G/T</td>
<td>0.189</td>
<td>0.096</td>
<td>0.016</td>
<td>4.81E-09</td>
<td>3.3</td>
<td>15,721</td>
<td>0.063</td>
<td>0.052</td>
<td>2.21E-01</td>
<td>0.2</td>
<td>2,147</td>
<td>0.093</td>
<td>2.88E-09</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WHR\textsubscript{adjBMI}</td>
<td>Women</td>
<td>rs140858719</td>
<td>1</td>
<td>85,203,061</td>
<td>SSX2IP</td>
<td>G/A</td>
<td>0.994</td>
<td>0.506</td>
<td>0.039</td>
<td>5.07E-08</td>
<td>0</td>
<td>11314</td>
<td>0.403</td>
<td>0.052</td>
<td>4.08E-01</td>
<td>0</td>
<td>834</td>
<td>0.502</td>
<td>3.69E-08</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WHR\textsubscript{adjBMI}</td>
<td>Women</td>
<td>rs378854</td>
<td>8</td>
<td>128,323,819</td>
<td>CASP8</td>
<td>G/T</td>
<td>0.787</td>
<td>0.062</td>
<td>0.015</td>
<td>3.34E-05</td>
<td>4.5</td>
<td>15,600</td>
<td>0.034</td>
<td>0.054</td>
<td>5.29E-01</td>
<td>73.2</td>
<td>1,730</td>
<td>0.060</td>
<td>2.94E-05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WHR\textsubscript{adjBMI}</td>
<td>Women</td>
<td>rs185693786</td>
<td>11</td>
<td>14,804,296</td>
<td>PDE3B</td>
<td>G/A</td>
<td>0.930</td>
<td>0.122</td>
<td>0.023</td>
<td>2.01E-07</td>
<td>0</td>
<td>15,601</td>
<td>0.17</td>
<td>0.095</td>
<td>4.50E-02</td>
<td>21.6</td>
<td>1,730</td>
<td>0.125</td>
<td>2.98E-08</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WHR\textsubscript{adjBMI}</td>
<td>Women</td>
<td>rs6499129</td>
<td>16</td>
<td>67,458,251</td>
<td>ZDHHC1/</td>
<td>A/C</td>
<td>0.434</td>
<td>0.045</td>
<td>0.012</td>
<td>1.12E-04</td>
<td>30.9</td>
<td>15,588</td>
<td>0.071</td>
<td>0.042</td>
<td>9.29E-02</td>
<td>41.2</td>
<td>1,730</td>
<td>0.047</td>
<td>3.07E-05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HSD111B2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AA: African ancestry; BMI: body mass index; Chr: chromosome; EA: European ancestry; EAF: effect allele frequency; HetISq: heterogeneity measured by I-square; SE: standard error; WHR\textsubscript{adjBMI}: waist-to-hip ratio adjusted for BMI

https://doi.org/10.1371/journal.pgen.1006719.t002
BMI loci remained significant ($P_{\text{locus}} < 0.05$) after adjustment for the number of independent variants tested at each locus. Sixteen (36%) and 22 (49%) of these 45 lead regional variants are in LD ($r^2 > 0.2$) with the EA BMI lead variants using 1000 Genomes AFR and CEU LD, respectively. Twenty-five of these variants are highly correlated with EA lead variants ($r^2 > 0.7$ in CEU) or had $\geq 1$ standard error decrease in effect sizes after conditional analyses, representing same association signals as in EA populations. Twenty-one (32%) lead regional variants for WHR$_{\text{adjBMI}}$ loci remained significant. Nine (43%) and seven (33%) of the 21 lead regional variants was in LD with the EA lead variant using 1000 Genomes AFR and CEU LD, respectively. Seven of these variants represented the same EA association in conditional analyses (S12 Table).

Fine mapping of novel AA loci and EA-AA transferable established loci

Among the locus-wide significant established loci (44 for BMI given two of 45 lead regional variants were identical in two loci, and 21 for WHR$_{\text{adjBMI}}$), and novel loci (three for BMI and six for WHR$_{\text{adjBMI}}$) derived from the sex-combined and sex-stratified analyses, we performed fine mapping to localize putative causal variants. We constructed 99% credible sets containing variants that jointly account for 99% posterior probability of driving the association in a locus using the corresponding sex-combined or sex-stratified meta-analysis results from AA, EA and combined ancestry (S13 Table). A smaller number of variants in a credible set represent a higher resolution of fine mapping and we considered a credible set containing $\leq 20$ variants as ‘tractable’ for follow up. The credible sets in the EA analyses were generally smaller than those in the AA given their larger sample size. As compared to the EA analyses, the number of tractable loci in the meta-analyses of AA and EA increased from 23 to 26 for BMI, and from 14 to 17 for WHR$_{\text{adjBMI}}$.

Among these 43 tractable loci, the lead variants in the combined ancestry analyses had posterior probability $\geq 0.95$ in six BMI loci (SEC16B, TLR4, STXBP6, NLRC3, FTO and MC4R) and seven WHR$_{\text{adjBMI}}$ loci (DCST2, PPARG, ADAMTS9, SNX10, KLF13, CMIP and PEMT) (S13 Table). Functional characterization of variants within the tractable credible sets revealed two loci contain nonsynonymous variants (ADCY3: rs11676272 S107P; SH2B1: rs7498665 T484A from the ATP2A1 locus), but they had low posterior probability to drive the respective associations (0.02 and 0.15, respectively) (S14 Table). On the other hand, the ADCY3 non-coding variants rs10182181 and rs6752378 had higher posterior probability (0.26–0.72) and are cis-eQTLs of ADCY3 and nearby genes. Several BMI loci including MTCH2, MAP2K5, NLRC3 and ATP2A1, and WHR$_{\text{adjBMI}}$ loci including TBX15-WARS2 and FAM13A, also contained cis-eQTL variants regulating nearby gene expression in subcutaneous and/or visceral adipose tissue (S14 Table).

Discussion

In our large-scale meta-analyses of GWAS in up to 52,895 and 23,095 individuals of African ancestry for BMI and WHR$_{\text{adjBMI}}$, respectively, we identified three novel (IRX4/IRX2, INTS10/LPL and MLC1) and seven established (SEC16B, TMEM18, GNPDA2, GALNT10, KLHL32, FTO and MC4R) BMI loci, as well as three novel (TCF7L2/HABP2, SSX2IP and PDE3B) and one established (ADAMTS9-AS2) WHR$_{\text{adjBMI}}$ loci in either sex-combined or sex-stratified analyses. By employing a recently developed method [23] to impute European GWAS summary statistics to the denser 1000 Genomes reference panel, followed by meta-analyses of both African and European ancestry individuals, we also identified three additional novel loci (SPRYD7/DLEU2, CASC8 and ZDHHC1/ HSD11B2) for WHR$_{\text{adjBMI}}$. While all lead variants from established loci are common (MAF $\geq 5\%$), four of the nine lead variants from novel loci.
were low frequency (0.5% ≤ MAF < 5%). In addition, the lead variants from established loci including TMEM18 and ADAMTS9-AS2 were absent in HapMap. Overall, these results suggest the deeper genome coverage and/or improved imputation quality using 1000 Genomes, and complemented with additional sex-stratified analyses, facilitate the discovery of novel loci and identification of variants with stronger effects in established loci.

Among the novel sex-specific BMI loci (IRX4/IRX2, INTS10/LPL and MLC1), we did not identify any putative coding variants or regulatory regions underlying our association signals. Additionally, no associations have been reported with other metabolic traits in these novel BMI-associated signals. The first lead variant rs112778462 is located between the IRX4 and IRX2 genes which are members of the Iroquois homeobox gene family. IRX2 expression has been associated with deposition of fat in the subcutaneous abdominal adipose tissue but no sex difference was observed [29–30]. IRX knock out mice demonstrated cardiomyopathy with compensated increased Irx2 expression [31]. The second lead variant rs149352150 is located between the INTS10 and LPL genes. LPL encoded lipoprotein lipase is expressed in several tissues including adipose to mediate triglyceride hydrolysis and lipoprotein uptake. The serum LPL mass [32] and LPL activity and fat cell size of adipose tissues at glutes and thigh [33] have been reported to be higher in women than in men. Previous GWAS demonstrated association of LPL with triglycerides and HDL cholesterol [34–35]. However, the reported lead variant rs12678919 was not in strong LD with rs149352150 (r^2 = 0.005 in AFR and 0.006 in EUR). The third lead variant rs56330886 is located in a gene-rich region on chromosome 22q13 including MLC1. No biological candidates are identified in this region, therefore further analyses may be needed to explain the causative mechanism for this association signal.

Among the novel WHR\_adjBMI loci, rs116718588 is located between TCF7L2 and HABP2. TCF7L2 is the most significant type 2 diabetes locus in African Americans [36] and other populations [37]. However, rs116718588 was not in LD (r^2 < 0.01 in AFR) with the reported type 2 diabetes associated variants. The second lead variant rs2472591 is located near SPRYD7, DLEU2 and TRIM13. This locus was associated with height in previous GWAS [6], but rs2472591 was not associated with height in our study (P > 0.05), suggesting different variants in this locus regulate different measures of body size. In addition, a surrogate of rs2472591, rs790943, is a cis-eQTL for TRIM13 [26] suggesting it may be the target gene. TRIM13 encodes an E3 ubiquitin-protein ligase involved in endoplasmic reticulum-associated degradation. The third lead variant rs140858719 is located between SSX2IP and LPAR3. LPAR3 is a plausible candidate as it encodes a receptor for lysophosphatidic acid (LPA). The autotaxin/LPA pathway mediates diverse biological actions including activation of preadipocyte proliferation [38], suppression of brown adipose differentiation [39], and promotion of systematic inflammation [40] which lead to increased risk for cardiometabolic diseases including obesity and insulin resistance [41–42]. LPA receptor 1 which is highly expressed in adipocytes and the gut primarily mediates these effects [43]. It has also been reported that LPA, via LPA1 and LPA3 receptors, mediated leukocytes recruitment and pro-inflammatory chemokine secretion during inflammation [44]. The fourth lead variant rs185693786 is located at intron 2 of PDE3B. The association signal spanned a large genomic region and harbors GWAS loci for adiponectin and height. Phosphodiesterase 3B is critical for mediating insulin/IGF-1 inhibition of cAMP signaling in adipocytes, liver, hypothalamus and pancreatic β cells [45]. Pde3b-knockout mice exhibited multiple alterations in regulation of lipolysis, lipogenesis, and insulin secretion, as well as signs of peripheral insulin resistance [46]. PDE3B expression has been reported to be higher in microvascular endothelial cell culture derived from skeletal muscles from male rats than in female rats [47]. The fifth lead variant rs6499129 is located intergenic between ZDHHC1 and HSD11B2. HSD11B2 encodes 11β-hydroxysteroid dehydrogenase type 2 which converts the active glucocorticoids to inactive metabolites. HSD2 activity was elevated in
severe obesity and negatively associated with insulin sensitivity [48]. HSD2 expression is higher in omental than abdominal subcutaneous adipose tissue which may contribute to adipocyte hypertrophy and visceral obesity [49]. The sixth lead variant rs378854 is located at the long non-coding RNA CASC8. Associations of variants at CASC8 have been reported for various cancers [50–52] but no association was reported for cardiometabolic traits.

In our SNP and locus transferability analyses, a moderate number of EA-derived BMI and WHR_{adjBMI} associated variants shared the same trait-raising alleles and displayed nominally significant associations in AA individuals, similar to previous findings [11–12]. While the BMI variants were similar in terms of their effect sizes and frequencies of trait-raising alleles between EA and AA populations, there were more discrepancies for WHR_{adjBMI} variants. In addition, a substantial proportion of lead regional variants in AA were not in strong LD with EA lead variants, suggesting AA populations either have different association signals or the results may be spurious. Taken together, only <30% of EA loci were associated with BMI and WHR_{adjBMI} in AA.

Trans-ethnic fine mapping improved resolution to refine putative causal variant(s) in some loci as compared to using EA studies alone. In the meta-analyses of AA and EA GWAS, four BMI loci (SEC16B, STXBP6, FTO and MC4R) and six WHR_{adjBMI} loci (PPARG, ADAMTS9, SNX10, KLF13, CMIP and PEMT) only contained one variant in the 99% credible sets. Among 16 BMI and 3 WHR_{adjBMI} loci that were examined in both the previous trans-ethnic meta-analysis studies using HapMap imputation [7–8] and the present study, the number of variants and the interval of credible sets were either the same or lower in the present study for 13 and 15 loci, respectively. The majority of credible variants are non-coding in those sets containing ≤20 variants. Several of them located at the MTCH2, MAP2K5, NLRC3, ATP2A1, TBX15-WARS2 and FAM13A loci are cis-eQTL variants regulating nearby gene expression in subcutaneous and/or visceral adipose tissue, suggesting the putative causal variants may have a regulatory role instead of directly altering protein structure and function. Despite the low posterior probabilities, the coding changes of credible variants at ADCY3 and SH2B1 suggest that they may be the causal genes in the respective loci modulating BMI. Further studies are warranted to delineate putative causal variants including functional annotation in trans-ethnic fine mapping efforts [53].

Our large-scale GWAS meta-analyses in African ancestry individuals imputed to the 1000 Genomes reference panel, complemented by imputation of European GWAS using summary statistics and additional sex-stratified analyses, boosts the study power and improves resolution, leading to the identification of nine novel loci and fine mapping 37 loci with tractable credible sets. We observed significant associations for variants with MAF ≥ 0.5%, but rare variants were unlikely to be detected due to limited power and poor imputation quality. Large scale sequencing studies are needed to evaluate the contribution of rare variants in modulating complex traits such as BMI and WHR. Given the substantially larger sample size in European than in African ancestry samples, the trans-ethnic fine mapping results are largely driven by variants showing strong associations in Europeans. Future trans-ethnic studies including additional non-European populations will further improve the fine mapping effort.

Materials and methods

Study design

We used a three-stage design to evaluate genetic associations with BMI and WHR_{adjBMI} in sex-combined and sex-stratified samples (S1 Fig). Stage 1 included GWAS meta-analyses in AA individuals and stage 2 included replication of top associations from stage 1. Stage 3 included meta-analysis of top associations from stages 1 and 2 AA studies and EA meta-analysis results.
In the discovery stage 1 of AAAGC, 17 GWAS of up to 42,752 AA individuals (16,559 men and 26,193 women; 41,696 African Americans and 1,056 Africans) were included for the BMI analyses. A total of 10 GWAS of up to 20,384 AA individuals (4,783 men and 15,601 women; all African Americans) were included for the WHR\textsubscript{adjBMI} analyses. For variants with $P < 1 \times 10^{-4}$ in either the sex-combined or the sex-stratified meta-analyses, stage 2 replication was performed in additional AA individuals from AAAGC (N = 10,143 for BMI, N = 2,711 for WHR\textsubscript{adjBMI}), followed by meta-analysis with EA individuals from the GIANT consortium (322,154 for BMI, 210,086 for WHR\textsubscript{adjBMI}). Variants that reached genome-wide significance ($P < 5 \times 10^{-8}$) were assessed for associations with BMI in two cohorts of children (N = 7,222). All AA participants in these studies provided written informed consent for the research, and approval for the study was obtained from the ethics review boards at all participating institutions. Detailed descriptions of each participating study and measurement and collection of height, weight, waist and hip circumferences are provided in S1 Text, S1 and S2 Tables.

Genotyping, imputation and quality control

Genotyping in each study was performed with Illumina or Affymetrix genome-wide SNP arrays. Pre-phasing and imputation of missing genotypes in each study was performed using MaCH\textsubscript{2}/minimac [20] or SHAPEIT2/IMPUTEv2 [21–22] using the 1000 Genomes Project cosmopolitan reference panel (Phase I Integrated Release Version 3, March 2012) [18]. The details of the array, genotyping and imputation quality-control procedures and sample exclusions for each study are listed in S3 Table. In general, samples reflecting duplicates, low call rates, gender mismatch, or population outliers were excluded. Variants were excluded by the following criteria: call rate $< 0.95$, minor allele count (MAC) $\leq 6$, Hardy-Weinberg Equilibrium (HWE) $P < 1 \times 10^{-4}$, imputation quality score $< 0.3$ for minimac or $< 0.4$ for IMPUTE, or absolute allele frequency difference $> 0.3$ compared with expected allele frequency (calculated as 1000 Genomes frequency of AFR $\times 0.8 + EUR \times 0.2$).

Performance of 1000 Genomes imputation in African ancestry

We evaluated the performance of 1000 Genomes imputation using the largest study, the Women’s Health Initiative (WHI) (N = 8,054). A total of 25.1 million variants with MAF $\geq 0.1\%$ were imputed to the 1000 Genomes reference panel. Of these, 98.1\% (8.8 million) common variants, 95.4\% (9.3 million) low frequency variants (0.5\% $<\text{MAF} < 5\%$), and 72.5\% (4.6 million) rare variants (0.1\% $<\text{MAF} < 0.5\%$) were well imputed with IMPUTE info scores $\geq 0.3$ (S4 Table). Notably, these frequencies are slightly lower than those obtained by imputation using 1000 Genomes phase 1 interim reference panel in Europeans [54]. However, 72.6\%, 95.5\% and 99.5\% of the common, low frequency and rare variants, respectively, from the 1000 Genomes reference panel were not present in the HapMap and therefore demonstrate deeper coverage of the genome, particularly for the low frequency and rare variants.

Study-level association analyses

At all stages, genome-wide association analyses were performed by each of the participating studies. BMI was regressed on age, age squared, principal components and study site (if needed) to obtain residuals, separately by sex and case-control status, if needed. WHR was regressed on age, age squared, principal components, BMI and study site to obtain residuals, separately by sex and case-control status. Principal components were included to adjust for admixture proportion and population structure within each study. Residuals were inverse-normally transformed to obtain a standard normal distribution with mean of zero and standard deviation of one. For studies with unrelated subjects, each variant was tested assuming an
additive genetic model with each trait by regressing the transformed residuals on the number of copies of the variant effect allele. The analyses were stratified by sex and case-control status (if needed). For studies that included related individuals, family based association tests were conducted that took into consideration the genetic relationships among the individuals. Sex stratified, case-control stratified and combined analyses were performed. Association results with extreme values (absolute beta coefficient or standard error ≥ 10), primarily due to small sample sizes and/or low minor allele count, were excluded for meta-analysis.

Imputation of European GWAS summary statistics to 1000 Genomes

The latest summary statistics of sex-combined and sex-stratified meta-analyses of BMI and WHRadjBMI imputed to the HapMap reference panel in EA from the Genetic Investigation of ANthropometric Traits (GIANT) consortium were obtained from http://www.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files [7–8]. These association summary statistics were used to impute z-scores of unobserved variants at the 1000 Genomes Project EUR reference panel (Phase 1 Integrated Release Version 3) using the ImpG program [23]. In brief, palindromic variants (AT/CG) and variants with allele mismatch with the reference were removed from the data. Using the ImpG-Summary method, the z-score of an unobserved variant was calculated as a linear combination of observed z-scores weighted by the variance-covariance matrix between variants induced by LD within a 1 Mb window from the reference haplotypes. The sample size of each unobserved variant was also interpolated from the sample sizes of observed variants using the same weighting method for z-score as

\[ N_i = \sum_{t=1}^{T} \frac{|w_{it}|}{\sum_{j=1}^{T} |w_{ij}|} N_i, \]

where \( T \) is the number of observed variants, \( w_{it} \) is the element of the covariance matrix \( \Sigma_{it} \), for the unobserved variant \( i \) and the observed variant \( t \) within window. The performance of imputation was assessed by \( r^2_{\text{pred}} \), with similar characteristics as the standard imputation accuracy metric \( r^2_{\text{hat}} \) [20]. Results of variants with \( r^2_{\text{pred}} \geq 0.6 \) were used in subsequent analyses.

Meta-analysis

In the discovery stage 1, association results were combined across studies in sex-combined and sex-stratified samples using inverse-variance weighted fixed-effect meta-analysis implemented in the program METAL [55]. The study-specific \( \lambda \) values of association ranged from 0.97 to 1.05 for BMI, and 0.98 to 1.05 for WHRadjBMI (S3 Table). Genomic control correction [56] was applied to each study before meta-analysis, and to the overall results after meta-analysis (\( \lambda = 1.07 \) for BMI, 1.01 for WHRadjBMI). Variants with results generated from < 50% of the total sample size for each trait were excluded. After filtering, the numbers of variants reported in the meta-analyses were 17,972,087 for BMI, and 20,502,658 for WHRadjBMI.

Variants with \( P < 1 \times 10^{-4} \) in stage 1 sex-combined or sex-stratified meta-analyses were carried forward for replication in additional AA individuals (stage 2) and EA individuals (stage 3). For each of the replication AA studies, trait transformation and association were performed as in stage 1 and results were meta-analyzed using the inverse-variance method in METAL. For the replication study in EA, HapMap imputed summary statistics of each trait from the GIANT consortium were used to impute z-scores of unobserved variants at the 1000 Genomes.

In stages 1 and 2, meta-analysis results of AA studies were combined using the inverse-variance weighted method. In all stages including both AA and EA studies, meta-analysis results expressed as signed z-scores were combined using the fixed effect sample size weighted method in METAL due to the lack of beta and standard error estimates from the ImpG program [23]. Evidence of heterogeneity of allelic effects between males and females, within and across stages were assessed by the \( I^2 \) statistic in METAL. Genome-wide significance was
declared at \( P < 5 \times 10^{-8} \) from each of the sex-combined and sex-stratified meta-analysis including AA and/or combined AA and EA individuals. Difference in effects between men and women was assessed using Cochran’s Q test and nominal \( P_{het} < 0.05 \) declared as significant. A lead variant in a locus was defined as the most significant variant within a 1 Mb region. A novel locus was defined as a lead variant with distance \( > 500 \) kb from any established lead variants reported in previous studies. By convention, a locus was named by the closest gene(s) to the lead variant.

**Conditional and joint analyses of summary statistics**

For the genome-wide significant loci identified in sex-combined and sex-stratified analyses in AA (stages 1+2), we used the program GCTA [57–58] to select the top independent associated variants from summary statistics of the meta-analyses. This method uses the LD correlations between variants estimated from a reference sample to perform an approximate conditional association analysis. We used 8,054 unrelated individuals of African ancestry from the WHI cohort with ~15.7M variants available as the reference sample for LD estimation. To select the top independent variants in the discovery and replication meta-analysis results, we first selected all variants that had \( P < 5 \times 10^{-8} \) and conducted analysis conditioning on the selected variants to search for the top variants iteratively via a stepwise model to select the independent variants from this list. Then we proceeded to condition the rest of the variants that had \( P > 5 \times 10^{-8} \) on the list of independent variants in the same fashion until no variant had conditional \( P \) that passed the significance level \( P < 5 \times 10^{-8} \). Finally, all the selected variants were fitted jointly in the model for effect size estimation.

We also tested if the genome-wide significant variants identified from sex-combined GWAS in AA and the locus-wide significant variants identified from sex-combined and sex-specific locus transferability studies in AA were independent from nearby established loci identified from EA studies [7–8]. First, the published lead variants from EA studies were used to search for all surrogate variants that were in high LD (\( r^2 > 0.8 \) in 1000 Genomes Project EUR population). Second, these variants were pruned to select only variants in low LD in AA (\( r^2 < 0.3 \) in the 1000 Genomes Project AFR population) to avoid collinearity in conditional analysis. Third, association analysis was conducted on the AA significant variants conditioned on the selected EA lead and surrogate variants, using the program GCTA and estimated LD correlation from the WHI cohort. For genome-wide significant loci, an AA derived association signal is considered as independent from the established EA signals when the difference in–log\( P < 3 \) and difference in effect size \( < 1 \) standard error after conditional analysis. For locus-wide significant loci, given the lower level of significance, independence is only considered as difference in effect size \( < 1 \) standard error after conditional analysis.

**SNP and locus transferability analyses**

We investigated the transferability of EA BMI and WHR associated variants and loci in AA individuals from stage 1 sex-combined and sex-stratified meta-analyses. First, we tested for replication of lead variants previously reported to be associated with BMI (176 variants from 170 loci) and WHR\(_{adjBMI}\) (84 variants from 65 loci) at genome-wide significance in sex-combined and sex-stratified analyses from the GIANT consortium studies [7–9]. We defined SNP transferability as an EA lead variant sharing the same trait-raising allele at nominal \( P < 0.05 \) in AA individuals. To account for differences in local LD structure across populations, we also interrogated the flanking 0.1 cM regions of the lead variants to search for the best variants with the smallest association \( P \) in AA individuals. Locus-wide significance was declared as \( P_{locus} < 0.05 \) when the distance to the closest gene(s) was less than 1 Mb.
0.05 by Bonferroni correction for the effective number of tests within a locus, estimated using the Li and Ji approach [59].

**Fine mapping analyses**

We compared the credible set intervals of established loci that showed locus-wide significance \(P_{\text{locus}} < 0.05\) in the sex-combined or sex-specific analyses from this study in summary statistics datasets including the 1000 Genomes imputed results from GIANT, AAAGC and meta-analysis of GIANT and AAAGC. In each dataset, a candidate region is defined as the flanking 0.1cM region of the lead variant reported by the GIANT consortium. Under the assumption of one causal variant in a region of \(M\) variants, the posterior probability of a variant \(j\) with association statistics \(Z\) driving the association, \(P(C_j|Z)\), was calculated using the formula:

\[
P(C_j|Z) = \frac{\exp(\frac{1}{2} z^2)}{\sum_{j=1}^{M} \exp(\frac{1}{2} z^2)}.
\]

A 99% credible set was constructed by ranking all variants by their posterior probability, followed by adding variants until the credible set has a cumulative posterior probability > 0.99 [53].

**Bioinformatics**

**Functional annotation of novel variants.** To determine whether any of our nine novel GWAS lead variants identified in the sex-combined and sex-specific analyses might be tagging potentially functional variants, we identified all variants within 1 Mb and in LD \(r^2 > 0.7\), 1000 Genomes AFR) with our lead variants. As such, we identified 137 variants and annotated each of them using ANNOVAR [60]. The predicted functional impact for coding variants were assessed via the Exome Variant Server (http://evs.gs.washington.edu/EVS/) for PhastCon, GERP [61], and PolyPhen [62], as well as SIFT [63].

We further characterized the variants that were in LD with the novel variants using the web-based tool RegulomeDB (http://regulomedb.org/) [24]. The variants that were likely to affect binding and linked to expression of a gene target (scores 1a-1f) based on “eQTL, transcription factor (TF) binding, matched TF motif, matched DNase footprint and DNase peak” or were only likely to affect binding (scores 2a-2c) based on “TF binding, matched TF motif, matched DNase footprint and DNase peak” were selected. For these variants, the sequence conservation (GERP and SiPhy [64]), the epigenomic data from the Roadmap Epigenomic project (ChromHMM states corresponding to enhancer or promoter elements, histone modification ChIP-seq peaks, and DNase hypersensitivity data peaks), the regulatory protein binding from the ENCODE project, the regulatory motifs based on commercial, literature and motif-finding analysis of the ENCODE project, and the eQTLs from Genotype-Tissue Expression (GTEx) project [65] were extract from web-based HaploReg v4 [25]. For variants within the tractable credible sets in the fine mapping analyses, similar analyses were also conducted.

**Cross-trait associations.** To assess whether the novel loci identified in the sex-combined and sex-specific analyses were associated with any related cardiometabolic and anthropometric traits, or may be in high LD with known eQTLs, we examined the NHGRI-EBI GWAS Catalog [27] and the GRASP (Genome-Wide Repository of Associations Between SNPs and Phenotypes) catalog [28] for reported variant-trait associations near our lead variants. We supplemented the catalogs with additional genome-wide significant associations of interest from the literature [7–9,66]. We used PLINK to identify variants within 1 Mb of lead variants. All variants within the specified regions with \(r^2 > 0.7\) (1000 Genomes AFR) were retained from the catalogs for further evaluation.
Power analysis

Given our sample sizes in the discovery and replication stages in our African ancestry populations, we have >80% power to detect variants explaining 0.08% variance for BMI that corresponds to effect sizes of 0.09 and 0.20 SD units for MAF of 0.05 and 0.01, respectively. For WHR_{adjBMI}, we have >80% power to detect variants explaining 0.18% variance that corresponds to effect sizes of 0.14 and 0.30 SD units for MAF of 0.05 and 0.01, respectively.

Supporting information

S1 Fig. Study design of GWAS meta-analyses and replications for BMI and WHR_{adjBMI}.
(PDF)

S2 Fig. Quantile-quantile plot of 1000 genomes phase 1 imputed discovery results and their associations to adult BMI in men and women of African ancestry using all variants and only variants outside of known GWAS loci.
(PDF)

S3 Fig. Quantile-quantile plot of 1000 genomes phase 1 imputed discovery results and their associations to adult BMI in men only and men only of African ancestry using all variants and only variants outside of known GWAS loci.
(PDF)

S4 Fig. Quantile-quantile plot of 1000 genomes phase 1 imputed discovery results and their associations to adult waist-to-hip ratio adjusted for BMI (WHR_{adjBMI}) in men and women of African ancestry using all variants and only variants outside of known GWAS loci.
(PDF)

S5 Fig. Quantile-quantile plot of 1000 genomes phase 1 imputed discovery results and their associations to adult waist-to-hip ratio adjusted for BMI (WHR_{adjBMI}) in women only and men only of African ancestry using all variants and only variants outside of known GWAS loci.
(PDF)

S6 Fig. Manhattan plot of 1000 genomes phase 1 imputed discovery results and their associations to adult BMI in men and women of African ancestry.
(PDF)

S7 Fig. Manhattan plot of 1000 genomes phase 1 imputed discovery results and their associations to waist-to-hip ratio adjusted for BMI (WHR_{adjBMI}) in men and women of African ancestry.
(PDF)

S8 Fig. Miami plot of 1000 genomes phase 1 imputed discovery results and their associations to adult BMI in women only (top) and men only (bottom) of African ancestry.
(PDF)

S9 Fig. Miami plot of 1000 genomes phase 1 imputed discovery results and their associations to adult waist-to-hip ratio adjusted for BMI (WHR_{adjBMI}) in women only (top) and men only (bottom) of African ancestry.
(PDF)

S10 Fig. Locuszoom plots using discovery results for established loci that reached genome-wide significance: (A) SEC16B, TMEM18, GNPDA2, GALNT10, KLHL32, FTO and MC4R for BMI in men and women combined; and (B) ADAMTS9-AS2 for waist-to-hip ratio adjusted
for BMI (WHRadjBMI) in men and women combined. All plots use AFR LD from the 1000 Genomes phase 1 reference panel. In each plot, the most significant variant within a 1Mb regional locus is highlighted. $P$-values for all variants including the most significant variant are based on the African ancestry discovery phase only (AA-Discovery). In addition, for the most significant variant, $P$-values are annotated and illustrated from the African ancestry discovery and replication phases (AA-Discovery+Replication).

**S11 Fig.** Correlation of effect sizes for (A) BMI and (B) WHRadjBMI, and effect allele frequencies for (C) BMI and (D) WHRadjBMI in European and African ancestry studies in SNP transferability analyses.

(PDF)

**S1 Table.** Study design and sample quality control of discovery and replication studies. (XLSX)

**S2 Table.** Study-specific descriptive statistics of discovery and replication studies. (XLSX)

**S3 Table.** Genotyping methods, quality control of variants, imputation, and statistical analysis in discovery and replication studies. (XLSX)

**S4 Table.** Comparison of coverage of variants using the 1000 Genomes and HapMap reference panels for imputation in the Women's Health Initiative study. (XLSX)

**S5 Table.** Comparison of lead variants between 1000 Genomes and HapMap imputed meta-analysis in AA in previously identified BMI loci in discovery and replication studies. (XLSX)

**S6 Table.** Associations of lead variants from novel and previously identified BMI and WHRadjBMI loci in combined and sex-stratified analyses of African ancestry discovery and replication samples. (XLSX)

**S7 Table.** Association of African Ancestry sex-combined genome-wide significant variants in children of African ancestry. (XLSX)

**S8 Table.** Putative coding or regulatory variants in linkage disequilibrium ($r^2 > 0.7$) with WHRadjBMI loci. (XLSX)

**S9 Table.** Previously-reported associations of novel BMI and WHRadjBMI loci with other traits in the GRASP Catalog. This table lists all previously-reported associations within 1 Mb (+/- 500 kb) and in high LD ($r^2 > 0.7$) with our lead novel SNPs along with relevant annotation (e.g. miRNA target binding site, variant location relevant to nearest gene, gene function prediction) reported in the GRASP Catalog. (XLSX)

**S10 Table.** Conditional analysis of African ancestry primary and secondary lead SNPs with European lead SNPs in previously identified BMI and WHRadjBMI loci. (XLSX)
S11 Table. SNP transferability of BMI and WHR_{adjBMI} lead SNPs from European sex combined and sex stratified GWAS in African ancestry individuals.
(XLSX)

S12 Table. Locus transferability and conditional analyses of European BMI and WHR_{adjBMI} loci in African ancestry individuals.
(XLSX)

S13 Table. Fine mapping of novel loci and previously identified loci with locus-wide significance in African ancestry individuals using 1000 Genomes imputed results from African, European and combined ancestries.
(XLSX)

S14 Table. Functional characterization of variants in tractable credible sets in meta-analysis of African and European ancestry GWAS.
(XLSX)

S1 Text. Supplementary note.
(DOCX)

S2 Text. Members of the BMDCS Group.
(DOCX)

Acknowledgments
We gratefully acknowledge the contribution of all participants from the various studies that contributed to this work.

Author Contributions

Conceptualization: CAH KEN MCYN RJFL.

Formal analysis: AC AEJ AML AS BEC BOT BP CTL DH DV DZ EBW GC GL HO JAB JAS JPB JDF JL JY KR KY LAL LD LRY MCYN MFF MGr MKW MAN MRI PM QD RR SMT SV TMB WMC WZha XG YHHH YLi YLu YS.

Project administration: AA ABZ AOI BAR BIF BM BMP BN BOT BSZ CAH CBA CDH CNR DCR DH DKA DMB DRW DSS DVC DWB EK EMJ EPB EVB HH IBB JC JGW JH JIR JLS JNH JSW KEN KLW LAC LB MCYN MF MKE MMS MFP MS OIO PJG RGZ RJFL RK RSC SAI SFAG SIB SJC SLRK SRP SSS TBH VLS WJB WZhe XZ.

Resources: AGF AOg BIF BMP BN BS BSZ DRW HH JAS JDF JIR KLN MAA MC MGa OO SA SFAG SLRK TOO UN WZha WZhe YDIC.

Supervision: CAH KEN MCYN RJFL.

Writing – original draft: AEJ CTL LAC LRY MCYN MFF MGr MKW YLu.

Writing – review & editing: AEJ BEC BMP CAH DCR DKA DMB JPB KEN KR KY LAC LRY MC MNCH MFF YLu MKW MAN MRI RJFL WMC XG YLu.

References


